Showing 4751-4760 of 5806 results for "".
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- BTL Files Suit Against Allergan, Alleges Misleading Advertisinghttps://practicaldermatology.com/news/btl-files-suit-against-allergan-alleges-misleading-advertising/2460288/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Foamix’s Rosacea Candidate Shows Promise in Phase 3 Studieshttps://practicaldermatology.com/news/foamixs-rosacea-candidate-shows-promise-in-phase-3-studies-1/2460286/Foamix Pharmaceuticals Ltd.’s FMX103 1.5% Topical Minocycline Foam for rosacea performed well in an integrated efficacy analysis of two pivotal Phase 3 clinical trials presented at the 17th Annual South Beach Symposium in Dermatology in Miami,
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- Allergan Launches New Philanthropic Program Benefitting Kids with Upper Limb Spasticityhttps://practicaldermatology.com/news/allergan-launches-new-philanthropic-program-benefitting-kids-with-upper-limb-spasticity/2460274/Allergan is launching the Be The Difference philanthropic program to support children and their families who may benefit from treatment with Botox (onabotulinumtoxinA) for pediatric upper limb spasticity. Botox is approved to treat increased muscle stiffness in children 2 to 17 years of
- Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-2020-aspire-higher-scholarship-program/2460273/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics opened of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a
- Derms Still Need Disaster Preparedness Traininghttps://practicaldermatology.com/news/derms-still-need-disaster-preparedness-training/2460271/The dermatology community is inadequately prepared for a biological disaster and would benefit from a formal preparedness training program, according to a study from the George Washington University (GW) that appears in the Jour
- Dermal Fillers Restore Youthful Facial Movement Toohttps://practicaldermatology.com/news/dermal-fillers-restore-youthful-facial-movement-too-1/2460269/Dermal fillers do more than just fill in wrinkles, they also restore a more youthful pattern of facial movement and expressiveness, according to a
- BioPharmX Corporation and Timber Pharmaceuticals LLC Announce Mergerhttps://practicaldermatology.com/news/biopharmx-corporation-and-timber-pharmaceuticals-llc-announce-merger/2460267/BioPharmX Corporation and Timber Pharmaceuticals LLC have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of BioPharmX's stockholders and Timber's members, a wholly-owned subsidiary of BioPharmX will be merged wit